Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response

Lior Katz, Javier P. Gisbert, Beth Manoogian, Kirk Lin, Casper Steenholdt, Gerassimos J. Mantzaris, Ashish Atreja, Yulia Ron, Arun Swaminath, Somal Shah, Ailsa Hart, Peter Laszlo Lakatos, Pierre Ellul, Eran Israeli, Mads Naundrup Svendsen, C. Janneke Van Der Woude, Konstantinos H. Katsanos, Laura Yun, Epameinondas V. Tsianos, Torben NathanMaria Abreu, Iris Dotan, Bret Lashner, Jorn Brynskov', Jonathan P. Terdiman, Peter D.R. Higgins, Maria Chaparro, Shomron Ben-Horin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

112 Scopus citations

Fingerprint

Dive into the research topics of 'Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response'. Together they form a unique fingerprint.

Medicine & Life Sciences